Drug
Odanacatib clinical trials
Also written MK-0822.
- studies test it
- 20
- open now
- 0
- in phase 3
- 7
- first study started
- 2004
How studies write it
Studies that test it under each name
Name
Development codes
- MK-0822
- 16
Studies by the year they started
20 studies that test it; most in 2004 (4)
| Year | Studies |
|---|---|
| 2004 | 4 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 5
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 0
Studies
Open first, then newest update. How each study uses odanacatib is read from its arms, and is right about nine times in ten.
Testing it · 20
- A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)TerminatedPhase 3Merck Sharp & Dohme LLCNCT00529373Written as Odanacatib
- Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)TerminatedPhase 3Merck Sharp & Dohme LLCNCT01803607Written as odanacatib
- Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)CompletedPhase 1Merck Sharp & Dohme LLCNCT01512693Written as MK-0822
- Safety and Tolerability of Odanacatib (0822-059)CompletedPhase 1Merck Sharp & Dohme LLCNCT01068262Written as Odanacatib
- Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)CompletedPhase 1Merck Sharp & Dohme LLCNCT01512667Written as MK-0822
- A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)CompletedPhase 3Merck Sharp & Dohme LLCNCT01120600Written as Odanacatib
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)CompletedPhase 2Merck Sharp & Dohme LLCNCT00885170Written as Odanacatib
- A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)TerminatedPhase 1Merck Sharp & Dohme LLCNCT01630616Written as Odanacatib
- Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)CompletedPhase 2Merck Sharp & Dohme LLCNCT00620113Written as Odanacatib
- Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)CompletedPhase 3Merck Sharp & Dohme LLCNCT00729183Written as Odanacatib
- A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)CompletedPhase 2Merck Sharp & Dohme LLCNCT00399802Written as Odanacatib
- A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)CompletedPhase 2Merck Sharp & Dohme LLCNCT00112437Written as Odanacatib
- A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)WithdrawnPhase 3Merck Sharp & Dohme LLCNCT00692458Written as Comparator: odanacatib
- A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)WithdrawnPhase 3Merck Sharp & Dohme LLCNCT00691899Written as odanacatib
- A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)CompletedPhase 1Merck Sharp & Dohme LLCNCT00770159Written as odanacatib
- A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00397683Written as MK0822
- Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)WithdrawnPhase 3Merck Sharp & Dohme LLCNCT01552122Written as Odanacatib
- A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)CompletedPhase 1Merck Sharp & Dohme LLCNCT00863525Written as odanacatib
- Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT00769418Written as odanacatib
- A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy VolunteersCompletedPhase 1Merck Sharp & Dohme LLCNCT00863590Written as odanacatib
Codes
What other systems call odanacatib · ClinicalTrials.gg INT005239
- MeSH (NLM) C527128odanacatibOne source NLM
- UNII (FDA) N673F6W2VHODANACATIBConfirmed FDA, NLM, Wikidata
- Wikidata Q2014070odanacatibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66981OdanacatibOne source FDA
- DrugBank DB06670One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C527128 | odanacatib | One source NLM |
| UNII (FDA) | N673F6W2VH | ODANACATIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q2014070 | odanacatib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66981 | Odanacatib | One source FDA |
| DrugBank | DB06670 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.